Overview of the drug development pipeline for renal anemia

It has been observed that renal anemia is the significant reduction in the circulation of red blood cells in the body and is one of the most common symptoms of chronic kidney disease. During this condition, kidneys cannot produce erythropoietin, a hormone that prompts bone marrow to produce red blood cells. Red blood cells contain hemoglobin, which carries oxygen to the organs and tissues in the body. The red blood cells in the people with anemia carry less oxygen, thereby affecting the tissues and organs associated with the heart and brain.

Renal anemia, also known as anemia owing to chronic kidney disease (CKD), is the loss of kidney functions. The pathophysiology of anemia in CKD is characterized by conditions such as weakness, fatigue, and headache, affecting the heart and brain adversely. Several public and private companies are focused on the development of drug molecules for the treatment of renal anemia. Monotherapy is emerging as the most efficient approach for the treatment of renal anemia.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for renal anemia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Pipeline analysis report on drug development for renal anemia: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of renal anemia. In addition to providing information on the various stages of molecules developed by companies for different indications, the pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• 3SBio
• Aevi Genomic
• Bayer

Therapeutic assessment of the drug development pipeline for renal anemia by route of administration

• Oral
• IV
• Subcutaneous
• IV + Subcutaneous
• Parenteral
• Unknown

The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for renal anemia by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for renal anemia are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug therapy molecules in the various development stages for renal anemia?
• What are the companies that are currently involved in the development of drug molecules for renal anemia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.